Table 3 Threshold effect analysis of SUA on all-cause, CVD, and cancer mortality
Threshold (mg/dL) | HR (95% CI) | ||
|---|---|---|---|
Univariate | Age-adjusted | Multivariatea | |
Male | |||
 All-cause mortality | |||
  ≤ 6.7 | 0.77 (0.65–0.92) | 0.86 (0.76–0.97) | 0.95 (0.80–1.13) |
  > 6.7 | 1.38 (1.03–1.85) | 1.22 (0.95–1.55) | 1.07 (0.90–1.26) |
 CVD mortality | |||
  ≤ 6.7 | 0.77 (0.60–1.00) | 0.89 (0.72–1.11) | 1.10 (0.85–1.43) |
  > 6.7 | 1.50 (1.13–2.00) | 1.33 (1.10–1.60) | 1.29 (1.05–1.58) |
 Cancer mortality | |||
  Monotonical | 0.79 (0.64–0.97) | 0.85 (0.72–1.00) | 0.80 (0.67–0.96) |
Female | |||
 All-cause mortality | |||
  ≤ 5.5 | 1.16 (0.95–1.42) | 0.93 (0.77–1.13) | 0.97 (0.77–1.22) |
  > 5.5 | 1.39 (1.24–1.55) | 1.24 (1.11–1.37) | 1.22 (1.07–1.39) |
 CVD mortality | |||
  ≤ 5.5 | 1.08 (0.74–1.56) | 0.95 (0.68–1.33) | 0.94 (0.63–1.39) |
  > 5.5 | 1.62 (1.28–2.06) | 1.49 (1.13–1.96) | 1.62 (1.24–2.13) |
 Cancer mortality | |||
  ≤ 5.5 | 1.26 (0.88–1.80) | 1.02 (0.71–1.45) | 1.07 (0.63–1.80) |
  > 5.5 | 1.57 (1.18–2.10) | 1.72 (1.31–2.28) | 1.95 (1.41–2.68) |